Track topics on Twitter Track topics that are important to you
Servier Pharma (Tianjin) signed a strategic cooperation agreement with Mitsubishi Tanabe Pharma to promote Mitsubishi's type 2 diabetes treatment drug Tenelia® (teneligliptin), a DPP-4 inhibitor, in mainland China. MTPC has completed the China Phase III clinical studies of Tenelia. The agreement was signed between Servier, a Paris headquartered biopharma, and Tianjin Tanabe Seiyaku, a JV formed by Tianjin Lisheng Pharma and Mitshubishi. More details....
Share this with colleagues:
Original Article: Servier Partners with Mitsubishi to Promote Diabetes Treatment in ChinaNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...